Press Release Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS Jun 15
Press Release Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee Jun 5